Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
|3||Active, not recruiting||
Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome
† Study has passed its completion date and status has not been verified in more than two years.